FATE – fate therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Form EFFECT FATE THERAPEUTICS INC
Form ARS FATE THERAPEUTICS INC For: Dec 31
Form DEFA14A FATE THERAPEUTICS INC
Form DEF 14A FATE THERAPEUTICS INC For: Jun 07
Form S-3 FATE THERAPEUTICS INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.